 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Eliminationhalf-life | 66 hours |
| Excretion | urine |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C16H15Cl2N |
| Molar mass | 292.20 g·mol−1 |
| 3D model (JSmol) | |
| |
Desmethylsertraline (DMS), also known asnorsertraline, is anactive metabolite of theantidepressantdrugsertraline. Like sertraline, desmethylsertraline acts as amonoamine reuptake inhibitor, and may be responsible for some of its parent's therapeutic benefits; however, the effects of DMS's main activity of increasing serotonin levels via binding to the serotonin transporter appears to be negligible as in vivo testing showed no measurable change in brain activity despite a nearly 20-fold increase in DMS blood levels compared to the EC50 (i.e. the amount required to achieve the desired effect in 50% of the population) of its parent drug sertraline.[1] DMS is significantly less potent relative to sertraline as aserotonin reuptake inhibitor (Ki = 76 nM vs. 3 nM, respectively), but conversely, is more balanced as a monoamine reuptake inhibitor (5-HT (Ki) = 76 nM;NE (Ki) = 420 nM;DA (Ki) = 440 nM), which has the effective result of DMS contrarily behaving as aserotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), with about 5.5-fold preference for inhibitingserotoninreuptake relative tocatecholamine reuptake.[2]
Dasotraline, astereoisomer of DMS, is also an SNDRI, and has been investigated for the potential clinical treatment ofmajor depressive disorder,attention-deficit disorder, andeating disorders, but has not been approved or marketed for any indication.
